Phase I-II Study of Low-Dose Azacitidine (Vidaza) in Patients With Chronic Myeloid Leukemia Who Have Minimal Residual Disease While Receiving Therapy With Tyrosine Kinase Inhibitors (VZ-CML-PI-0236)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Protein tyrosine kinase inhibitors
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 15 Aug 2019 Status changed from active, no longer recruiting to completed.
- 19 Oct 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 19 Oct 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.